LOP 001
Alternative Names: LOP-001Latest Information Update: 09 Oct 2023
At a glance
- Originator Guangzhou Zhaoke Lian Fa Pharmaceutical
- Developer Guangzhou Zhaoke Lian Fa Pharmaceutical; Lee's Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Cancer
Most Recent Events
- 04 Oct 2023 Registered for Cancer in China (unspecified route) prior to October 2023 (Lee's Pharmaceutical pipeline, October 2023)
- 01 Feb 2023 Preregistration for Cancer is ongoing in China (unspecified route) (Lee's Pharmaceutical pipeline, February 2023)
- 09 Dec 2020 Preregistration for Cancer in China (unspecified route), prior to December 2020 (Lee's Pharmaceutical pipeline, December 2020)